Overview

Tislelizumab Combined With Surufatinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Oligometastatic CRC

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

A Phase II Study to Assess the Efficacy and Safety of Tislelizumab Combined With Surufatinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Oligometastatic Colorectal Cancer

Phase:

Phase 2

Details

Lead Sponsor:

Huazhong University of Science and Technology